Compounders Research Compare

Oncolytics Biotech Inc.(ONCY)

Biotechnology · San Diego, CA

$0.60+0.00 (+0.50%)

Delayed quote: Oct 6, 2026, 3:15 PM EDT

About Oncolytics Biotech Inc.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

San Diego, CA

29 employees

www.oncolyticsbiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jared Kelly

View full financials

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T19:17:57.291Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:17:57.291Z.

Quote observation: 2026-10-06T19:15:22.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 60,206,565
TTM free cash flow · period ending 2026-06-30: -23,124,752.245999996

FMP input reference: d71c6897c98d436948f76d79272a6a7ae3c560285f8867db41996dc6a6301e16

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ONCY Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

ONCY Competitors' Price/FCF Ratio

Oncolytics Biotech Inc.

Current

Market Cap

$60.21M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Kalaris Therapeutics Inc

Market Cap

$60.46M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Xilio Therapeutics, Inc.

Market Cap

$60.49M

Price/FCF Ratio

N/A

TTM Avg

2.61

3Y Avg

2.61

5Y Avg

2.61

PDS Biotechnology Corporation

Market Cap

$60.68M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Fractyl Health, Inc.

Market Cap

$60.95M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Adicet Bio, Inc.

Market Cap

$59.01M

Price/FCF Ratio

N/A

TTM Avg

98.33

3Y Avg

98.33

5Y Avg

98.33

Connect Biopharma Holdings Limited

Market Cap

$58.75M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MiNK Therapeutics, Inc.

Market Cap

$58.54M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Heron Therapeutics, Inc.

Market Cap

$61.95M

Price/FCF Ratio

N/A

TTM Avg

1.90

3Y Avg

1.90

5Y Avg

1.90

Boundless Bio, Inc.

Market Cap

$58.21M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Oncolytics Biotech Inc. (ONCY)	$60.21M	N/A	N/A	N/A	N/A
Kalaris Therapeutics Inc (KLRS)vs ›	$60.46M	N/A	N/A	N/A	N/A
Xilio Therapeutics, Inc. (XLO)vs ›	$60.49M	N/A	2.61	2.61	2.61
PDS Biotechnology Corporation (PDSB)vs ›	$60.68M	N/A	N/A	N/A	N/A
Fractyl Health, Inc. (GUTS)vs ›	$60.95M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$59.01M	N/A	98.33	98.33	98.33
Connect Biopharma Holdings Limited (CNTB)vs ›	$58.75M	N/A	N/A	N/A	N/A
MiNK Therapeutics, Inc. (INKT)vs ›	$58.54M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$61.95M	N/A	1.90	1.90	1.90
Boundless Bio, Inc. (BOLD)vs ›	$58.21M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics